Log in
NASDAQ:PRLD

Prelude Therapeutics Stock Forecast, Price & News

$30.06
+0.44 (+1.49 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$29.73
Now: $30.06▼
$31.72
50-Day Range N/A
52-Week Range
$23.69
Now: $30.06▼
$50.19
Volume134,771 shs
Average Volume431,056 shs
Market Capitalization$1.28 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.15 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRLD
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.preludetx.com
Phone302-644-5427
Employees51

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares42,460,000
Market Cap$1.28 billion
Next Earnings DateN/A
OptionableNot Optionable
$30.06
+0.44 (+1.49 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRLD News and Ratings via Email

Sign-up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Prelude Therapeutics (NASDAQ:PRLD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Prelude Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prelude Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Prelude Therapeutics.

What price target have analysts set for PRLD?

4 Wall Street analysts have issued 1-year price objectives for Prelude Therapeutics' stock. Their forecasts range from $34.00 to $40.00. On average, they anticipate Prelude Therapeutics' share price to reach $37.75 in the next year. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for Prelude Therapeutics.

Who are some of Prelude Therapeutics' key competitors?

Some companies that are related to Prelude Therapeutics include Emergent Biosolutions (EBS), Allogene Therapeutics (ALLO), Rezolute (RZLT), BridgeBio Pharma (BBIO), Berkeley Lights (BLI), Repare Therapeutics (BLI), ELEKTA AB/ADR (EKTAY), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Change Healthcare (CHNG), NeoGenomics (NEO), Aurora Cannabis (ACBFF), China Biologic Products (CBPO) and Healthequity (HQY).
View all competitors.

Who are Prelude Therapeutics' key executives?

Prelude Therapeutics' management team includes the following people:
  • Dr. Krishna Vaddi D.V.M., Ph.D., Founder, CEO & Director (Age 55)
  • Mr. Brian D. Piper M.B.A., MBA, Chief Financial Officer (Age 48)
  • Dr. Peggy A. Scherle Ph.D., Chief Scientific Officer (Age 59)
  • Mr. Christopher Pierce M.B.A., Exec. VP & Chief of Bus. Operations (Age 40)
  • Dr. David J. Mauro, Chief Medical Officer (Age 55)

When did Prelude Therapeutics IPO?

(PRLD) raised $149 million in an IPO on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO.

What is Prelude Therapeutics' stock symbol?

Prelude Therapeutics trades on the NASDAQ under the ticker symbol "PRLD."

When does the company's quiet period expire?

Prelude Therapeutics' quiet period expires on Wednesday, November 4th. Prelude Therapeutics had issued 8,325,000 shares in its public offering on September 25th. The total size of the offering was $158,175,000 based on an initial share price of $19.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prelude Therapeutics' stock price today?

One share of PRLD stock can currently be purchased for approximately $30.06.

How big of a company is Prelude Therapeutics?

Prelude Therapeutics has a market capitalization of $1.28 billion. Prelude Therapeutics employs 51 workers across the globe.

What is Prelude Therapeutics' official website?

The official website for Prelude Therapeutics is www.preludetx.com.

How can I contact Prelude Therapeutics?

The company can be reached via phone at 302-644-5427.

This page was last updated on 10/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.